ArticleJournal of ovarian research2025
The lncrna HMMR-AS1 promotes the malignant progression of ovarian cancer cells by regulating the miR-627-3p/PTN axis.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Expression of long non‑coding RNAs DIAPH3‑AS1, HMMR‑AS1, and SPATA3‑AS1 in patients with colorectal cancer: association with chemotherapy response and clinicopathological features.Molecular biology reports · 2026Article
- Article
- Integrated analysis of single-cell and bulk transcriptomes reveals the prognostic value of polyamine metabolism biomarkers and immune microenvironment features in gastric cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLncRNAs are crucial regulators of ovarian cancer, playing a significant role in malignant transformation and closely linked to poor prognosis. Therefore, it is crucial to investigate the impact of lncRNAs on the malignant biological behavior of ovarian cancer and to understand their underlying molecular mechanisms.
methodsGene expression levels were measured using qRT-PCR. The malignant biological behavior of cells was assessed through cell biological function assays. The binding sites of target genes were predicted through bioinformatics analysis, and gene targeting relationships were verified using a dual-luciferase reporter gene(DLRG) assay. Protein expression levels were analyzed using Western blotting.
resultsIn ovarian cancer cells, the expression levels of HMMR-AS1 and PTN were upregulated, whereas the expression of miR-627-3p was downregulated. Cell biological function experiments demonstrated that HMMR-AS1 and PTN could enhance the malignant behavior of ovarian cancer cells, while miR-627-3p exhibited the opposite effect. The DLRG assay indicated that lncRNA HMMR-AS1 directly targets miR-627-3p, with PTN identified as the target gene of miR-627-3p. Western blotting indicated that lncRNA HMMR-AS1 promoted the expression of PTN protein, while miR-627-3p inhibited it. Furthermore, it was demonstrated that miR-627-3p or PTN could partially reverse the effects of lncRNA HMMR-AS1 on the malignant phenotype of ovarian cancer cells.
conclusionIn summary, HMMR-AS1 is highly expressed in ovarian cancer and plays a carcinogenic role by regulating the miR-627-3p/PTN axis and suggest that targeting HMMR-AS1 is a potential strategy for ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.